Cambrian Bio vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 36)
Cambrian Bio logo

Cambrian Bio

EmergingLife Sciences & BioTech

Aging Biology Drug Development — Distributed Biotech Model

Cambrian Bio is a New York-based clinical-stage biopharmaceutical company founded in 2019 that develops therapeutics targeting the biology of aging; operates a distributed development model with seven pipeline companies;

AI VisibilityBeta
Overall Score
D36
Category Rank
#101 of 198
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
31
Gemini
32

About

Cambrian Bio is a clinical-stage drug development company founded in 2019 and headquartered in New York City. The company's mission is to build medicines that redefine healthcare by developing therapeutics that prevent and treat age-related chronic diseases — extending the period of life spent in good health (healthspan). Rather than developing all drug programs in-house, Cambrian operates as a Distributed Development Company (DisCo): it provides capital, infrastructure, and strategic support to a portfolio of independent R&D teams, each advancing a program targeting a distinct biological driver of aging.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#101
Category Rank
#11
75
AI Consensus
68
stable
Trend
stable
35
ChatGPT
71
31
Perplexity
68
32
Gemini
80
41
Claude
77
32
Grok
69

Key Details

Category
Aging Biology Drug Development — Distributed Biotech Model
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.